Tasimelteon

他司美琼

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameTasimelteon
Drug Alias Name他美替安Tasimelteonum他美替胺HetliozVE-162 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMelatonin receptor agonists
TargetsMelatonin receptor
Therapy Area/IndicationsAutism Spectrum DisorderDepressive Disorder, MajorRenal Insufficiency +[10] 
Global Approved IndicationsSleep Disorders, Circadian Rhythm
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/01/31
Country/TerritoryCanadaUnited StatesTurkey +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesVanda Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesVanda Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsAutism Spectrum DisorderSleep Wake DisordersSmith-Magenis Syndrome +[5] 
Inactive IndicationsDepressive Disorder, MajorRenal InsufficiencySleep Initiation and Maintenance Disorders +[5] 

Other Information

ATC CodeN05CH03
Related LinksWikipediaDrugBankKEGG